HPM Announces Firm and Attorney Selection for 2026 Chambers USA Guide

Key Takeaways

• HPM earns Band 2 nationwide in Food & Beverages regulatory law
• Ricardo Carvajal ranked Band 1, top food‑beverage regulator
• Firm placed Band 3 in DC healthcare regulatory, showing regional strength
• Anne Walsh recognized in both regulatory and white‑collar crime rankings
• Chambers USA ranking boosts HPM’s market visibility and client trust

Pulse Analysis

Chambers USA has long been the gold standard for legal market intelligence, employing independent researchers to evaluate firms on depth of expertise, client feedback, and case outcomes. Rankings such as Band 1 through Band 6 signal a firm’s relative strength in specific practice areas, and they are frequently consulted by corporate counsel and in‑house legal teams when selecting external advisors. For regulatory practitioners, especially those navigating the complex FDA landscape, a high Chambers placement can differentiate a firm in a crowded marketplace and justify premium billing rates.

HPM’s 2026 rankings reflect a strategic focus on sectors where FDA oversight is intensifying. The firm’s Band 2 placement nationwide in Food & Beverages Regulatory & Litigation aligns with heightened scrutiny of labeling, nutrition claims, and supply‑chain compliance. Meanwhile, its Band 3 ranking in DC Healthcare Pharmaceutical/Medical Products Regulatory highlights deep expertise in drug and device approvals, a critical advantage as the industry accelerates innovation. Individual accolades—Ricardo Carvajal’s Band 1 in Food & Beverages and Kurt Karst’s Band 2 in Healthcare—demonstrate that HPM’s talent pool is recognized for both technical acumen and client service.

The practical impact of these rankings is immediate. Prospective clients often use Chambers data as a shortlist filter, meaning HPM’s elevated profile can translate into new engagements across biotech, consumer health, and life‑science firms. Existing clients gain reassurance that their counsel is validated by an independent, reputable source, strengthening long‑term relationships. Looking ahead, the firm’s continued investment in FDA regulatory expertise positions it to capture emerging opportunities in areas such as digital health, AI‑driven medical devices, and novel food technologies, ensuring its relevance in an evolving compliance environment.